Bluenote powers intelligent agents for life sciences with Claude

Bluenote uses Claude to build AI agents that power critical operations for life sciences organizations—from regulatory workflows and technical documentation to manufacturing and supply chain operations—enabling researchers to focus on science instead of paperwork.

With Claude, Bluenote agents:

• Generate complex multi-hundred page scientific documents with in-text tables, figures and citations in minutes.
• Accelerate regulatory and compliance document production by 50-75%.
• Enable scientists to parse complex protocols and execute their analyses 10x faster.
• Identify gaps in existing documentation based on the latest regulatory guidelines, and propose opportunities for increased compliance and quality.
• Securely retrieve data from clients’ data warehouses and quality management systems for end-to-end data traceability and consistency.

Building agents for highly regulated biomedical operations

Bringing a new treatment to market demands as much paperwork as it does research. For example, regulatory submissions, clinical trial reports, and quality validations are all essential parts of the process, but can take days or weeks of a researcher's time—time spent on documentation that could be spent on medical breakthroughs.

Bluenote deploys AI agents that automate this critical, but often manually-intensive and tedious work. Their agents process regulatory documents, generate technical reports with proper citations, and handle complex multi-step workflows—all with robust guardrails, data traceability, and highlighted calls to action for human experts to contribute additional context and review.

"No PhD scientist with 20 years of experience wants to spend half their time on FDA paperwork," explains Fatima Sabar, CEO and Founder of Bluenote. By integrating with existing systems and data warehouses, Bluenote meets its subject matter experts where and how they work, without disrupting established practices or compromising regulatory standards.

Grounded in a decade of building AI-powered products for scientists and clinicians, Bluenote was founded to bring that same trust and precision to life sciences operations. “Working with Claude helps us bridge the gap between cutting-edge, fast-moving AI and the deliberate, high-stakes work of science.” Sabar adds, “Every breakthrough in AI is a chance to make life sciences faster, safer, and drive operational excellence.”

Why Bluenote chose Claude

In an industry where trust is paramount, Bluenote partners with AI leaders who share their commitment to responsibility and precision. "What brought us to Claude was deep alignment around reliable and responsible AI,” says Sabar. "In life sciences, the bar is extremely high for accuracy, traceability, interpretability, and data provenance."

Bluenote employs a sophisticated model orchestration approach, with Claude as their default model for scientific, technical reports. "We support a suite of foundation models behind the scenes and use smart routing to pick the best model for each task," explains Bluenote CTO and Founder, Katsuya Noguchi. "Claude is our default for high-stakes regulatory and compliance documentation.”

Claude's citation capabilities are crucial for regulatory documentation. "For medical and technical documentation, tracing content back to source data at a granular level is critical for quality control and audits,” Noguchi adds. "Claude allows us to deliver high quality, reliable outputs that can be traced back to sources for our clients."

How Bluenote's agents transform life sciences workflows

Bluenote built three types of specialized agents using Claude:

• Document processing agents extract key information from scientific documents in minutes instead of hours. These agents scan through hundreds of pages to identify critical data points, research findings, and regulatory requirements.
• Technical documentation agents create regulatory documents with proper citations. These agents generate study reports, validation documentation, and compliance forms needed throughout the drug and device development process.
• Multi-step workflow agents automate complex processes from start to finish. These agents handle analyses, assessments, and document or form generation across multiple stages with minimal supervision while maintaining strict regulatory compliance.

Intelligent agents delivering measurable impact

Claude-powered agents create substantial value for Bluenote's life sciences clients—transforming critical workflows while maintaining the rigorous quality standards required in healthcare. Rather than providing isolated point solutions, Bluenote's agents deliver comprehensive support across the entire life sciences lifecycle.

Guardant Health, a leading precision oncology company, has integrated Bluenote's AI agents across key operations. Many of their workflows involve complex scientific and regulatory documentation that must adhere to numerous guidelines.

“With Bluenote's platform, we leverage the most advanced AI models that are optimized for each task,” explains Kenny Speer, Vice President of Bioinformatics Software Engineering at Guardant Health. “Bluenote’s AI agents powered by Claude generate first drafts of critical documents in minutes rather than days, while intelligently flagging areas that need human expert review. In lab operations, our QC agents have boosted specialized workflow efficiency by 40-50%. By equipping our teams with these sophisticated tools, we're accelerating how quickly we can move lifesaving innovations to patients."

Guardant’s perspective is echoed more broadly across the industry by leaders who see AI agents as a way to accelerate timelines without compromising quality.

“My 20+ years as a transplant surgeon taught me that for patients waiting for better therapies, time is the most precious resource,” explains Dr. Eliezer Katz, Chief Medical Officer of Eledon Pharmaceuticals. “Over the years, I’ve observed the parallel advancement of technology and medicine—and now, with the emergence of AI, we’re at the start of another transformative chapter. As CMO, I’m excited to see reliable and intelligent AI agents redefine drug development timelines. Across critical functions like Clinical Operations, CMC, and Safety, we can streamline operational complexity—all while preserving the quality standards that ensure patient safety. When we reduce development timelines, we’re not just improving operational metrics—we’re giving patients back precious days of quality life.”

Accelerating biomedical innovation through AI partnership

Bluenote's journey with Claude-powered agents is rapidly expanding. Biopharma leaders working to tackle the world’s toughest diseases are partnering with Bluenote to develop increasingly sophisticated agents that handle more complex work across the drug, device and diagnostic lifecycle.

“Our vision is to enable every life sciences organization to increase their operational velocity and get their safe and effective biomedical breakthroughs into the hands of patients as quickly as possible. Every day counts,” said Sabar.

The future promises agents that not only process documents and execute operational workflows, but also those that actively contribute to scientific processes. As Claude's capabilities advance, Bluenote envisions agents that can analyze vast repositories of institutional data, generate novel hypotheses, and act as true copilots for every scientist and life sciences professional.

“We envision Bluenote as a deeply embedded layer of intelligence that supports life sciences from discovery through development and delivery, and evolves alongside the science itself.” says Sabar. “Partnering with Anthropic means we can bring the most advanced AI capabilities into life sciences operations—while holding to the highest standards of accuracy, traceability, and quality.”

For patients waiting for life-saving treatments, this collaboration represents hope. Every hour saved from administrative tasks is an hour that scientists can dedicate to innovation. In this vision of the future, AI augments human expertise, creating a world where medical breakthroughs happen faster and reach those who need them most.